Search

Your search keyword '"Calabro L."' showing total 109 results
Start Over Author "Calabro L."
109 results on '"Calabro L."'

1. Seroprevalence of Human Herpes virus-8 (HHV-8) among Children Attending an Emergency Room in South-Eastern Nigeria

Author

Ikpatt OF, Ekanem EE, Calabro L, Ogon PM, and Chieco-Bianchi L.

Subjects
Medicine
Abstract

Summary: The seroprevalence of Human herpesvirus-8 (HHV-8) was studied in 56 children aged two to 14 years. Subjects were children seen consecutively in the Children Emergency Room of the University of Calabar Teaching Hospital in January 2000. Sera from the children were screened for antibodies to the small capsid related protein encoded by ORF 65 (Lytic antigen) by the ELISA technique and Latency Associated Nuclear Antigen (LANA) by the immunoflourescent assay. Of the 56 children, 42 (76.9 per cent) had antibodies to at least, one of the antigens. The rate of infection correlated positively with age (r= 0.45; p

Published
2024

2. 123P A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1/PD-L1 resistant melanoma or NSCLC patients: The run-in phase of the NIBIT Foundation ML1 study

Author

Di Giacomo, A.M., primary, Rossi, G., additional, Calabro, L., additional, Pascucci, A., additional, Vegni, V., additional, Simonetti, E., additional, Colucci, M., additional, Valente, M., additional, Gibilisco, G., additional, Frongia, F., additional, Lofiego, M.F., additional, Amato, G., additional, Keer, H.N., additional, Oganesian, A., additional, Chan, D., additional, Giannarelli, D., additional, Ceccarelli, M., additional, Anichini, A., additional, Covre, A., additional, and Maio, M., additional

Published
2023
Full Text
View/download PDF

3. 113P A multidisciplinary management of immune-checkpoint inhibitor (ICI)-related pneumonitis to improve its clinical management

Author

Valente, M., primary, Colucci, M., additional, Vegni, V., additional, Croce, V., additional, Bellan, C., additional, Rossi, G., additional, Gibilisco, G., additional, Frongia, F., additional, Guazzo, R., additional, Ghiribelli, C., additional, Savelli, V., additional, Ravara, M., additional, Sani, T., additional, Simonetti, E., additional, Maio, M., additional, Calabro, L., additional, and Di Giacomo, A.M., additional

Published
2023
Full Text
View/download PDF

5. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

Author

Di Giacomo, A.M., Ascierto, P.A., Queirolo, P., Pilla, L., Ridolfi, R., Santinami, M., Testori, A., Simeone, E., Guidoboni, M., Maurichi, A., Orgiano, L., Spadola, G., Del Vecchio, M., Danielli, R., Calabrò, L., Annesi, D., Giannarelli, D., Maccalli, C., Fonsatti, E., Parmiani, G., and Maio, M.

Published
2015
Full Text
View/download PDF

6. 704TiP SAR445256 (KY1044) in combination with atezolizumab in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)

Author

Patel, M., primary, Ascierto, P.A., additional, Thistlethwaite, F., additional, Adkins, D.R., additional, Meucci Villaflor, V., additional, Galizia, D., additional, Calabro, L., additional, Di Maio, M., additional, D'Ambrosio, C., additional, Bertolini, A., additional, Damato, A., additional, Deantonio, C., additional, Yang, Y., additional, Kurup, D., additional, and Abbadessa, G., additional

Published
2022
Full Text
View/download PDF

10. Impact of chronic exposure to 5-alpha reductase inhibitors on the risk of hospitalization for COVID-19: A case-control study in male population from two COVID-19 regional centers of Lombardy, Italy

Author

Lazzeri, M., Duga, S., Azzolini, E., Fasulo, V., Buffi, N., Saita, A., Lughezzani, G., Paraboschi, E. M., Hurle, R., Nobili, A., Cecconi, M., Guazzoni, G., Casale, P., Asselta, R., Accornero, S., Aghemo, A., Alfarone, L., Ali, H., Aloise, M., Angelini, C., Arcari, I., Arosio, P., Baccarin, A., Badalamenti, S., Baggio, S., Balzarini, L., Barbagallo, M., Barberi, C., Barbic, F., Barbieri, V., Barbone, A., Basciu, A., Benvenuti, C., Bianchi, I., Bocciolone, M., Bonifacio, C., Borea, F., Borroni, M., Bresciani, G., Brunetta, E., Bulletti, C., Cadonati, C., Calabro', L., Calatroni, M., Caltagirone, G., Calvetta, A. A., Cannata, F., Canziani, L., Capogreco, A., Capretti, G. L., Carlani, E., Carrone, F., Casana, M., Castelli, A., Ceribelli, A., Ceriotti, C., Ciccarelli, M. C., Cimino, M., Citterio, G., Ciuffini, L., Colaizzi, C., Colapiet-Ro, F., Costa, G., Cozzi, O., Craviotto, V., Crespi, C., Crippa, M., D'Antuono, F., D'Orazio, F., Da Rio, L., Dal Farra, S., D'Antonio, F., De Ambroggi, G., De Donato, M., De Lucia, F., De Nittis, P., De Santis, M., Delle Rose, G., Desai, A., Di Pilla, M., Dipaola, F., Dipasquale, A., Droandi, G., Altieri, V., Fazio, R., Fedeli, C., Ferrante, G., Ferrara, E. C., Ferrari, M. C., Ferri, S., Folci, M., Foresti, S., Franchi, E., Fraolini, E., Furfaro, F., Galimberti, P., Galtieri, A., Gavazzi, F., and Generali, E.

Subjects
Male, SARS-CoV-2, Urology, COVID-19, Middle Aged, 5-alpha reductase inhibitors, Androgens, Sex, Hospitalization, Nephrology, Case-Control Studies, Humans, Female, Aged
Abstract

There are sex differences in vulnerability to Coronavirus disease 2019 (COVID-19). The coronavirus S protein mediates viral entry into target cells employing the host cellular serine protease TMPRSS2 for S-protein priming. The TMPRSS2 gene expression is responsive to androgen stimulation and it could partially explain sex differences. We hypothesized that men chronically exposed to 5-alpha reductase inhibitors (5ARIs) for benign prostate hyperplasia (BPH) have a lower risk of hospitalization for COVID-19.This is a population-based case-control study on consecutive patients positive for SARS-CoV-2 virus who required hospitalization for COVID-19 (cases), age-matched to beneficiaries of the Lombardy Regional Health Service (controls). Data were collected by two high-volume COVID-19 regional centers of Lombardy (Italy). The primary outcome was to compare the prevalence of patients chronically exposed to 5ARIs, who required hospitalization for COVID-19, with the one of controls.Overall, 943 males were enrolled; 45 (4.77%) were exposed to 5ARI. COVID-19 patients aged55 years under 5ARI treatment were significantly less than expected on the basis of the prevalence of 5ARI treatment among age-matched controls (5.57 vs. 8.14%; P=0.0083, 95% CI: 0.75-3.97%). This disproportion was higher for men aged65 (7.14 vs. 12.31%; P=0.0001, 95% CI: 2.83-6.97%). Eighteen 5ARIs-patients died; the mean age of men who died was higher than those who did not: 75.98±9.29 vs. 64.78±13.57 (P0.001). Cox-regression and multivariable models did not show correlation between 5ARIs exposure and protection against intensive care unit admission/death.Men exposed to 5ARIs might be less vulnerable to severe COVID-19, supporting its use in disease prophylaxis.

Published
2022

11. A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation

Author

Maio M., Lahn M., Di Giacomo A. M., Covre A., Calabro L., Ibrahim R., Fox B., Abrignani S., Paola A., Anichini A., Ardizzoni A., Gregorio A., Azab M., Ballas M., Barberis M., Bayless N. L., Bell B., Bifarini A., Blank C., Brodin P., Camerini R., Ennio C., Ceccarelli M., Francesca C., Connolly J., Sandra C., Cornelissen R., Eggermont A., Eid J., Fajgenbaum D., Ferretti E., Ferrone S., Finotello F., Flaherty K., Ester F., Elisabetta F., Fridman C. S., Fridman W. H., Garcia P., Gherardini P. F., Goonewardene A., Hacking G., Heller K., Hulett T. W., Michael I., Jacobson D., Janek M., Joho S., Keer H., Kleif S., Kotecha N., Kotter M., Krogan N., Lanzavecchia A., Locatelli F., Lollini P. -L., Mantovani A., Melacarne A., Melillo G., Menden M., Minerva D., Moretta L., Namouni F., Natali P. G., Necchi A., Nistico P., Cosimo P., Giuseppe P., Pardoll D., Paz-Ares L., Plessala K., Peters S., Prins R. M., Provendier O., Rappuoli R., Rescigno M., Ruettinger D., Seliger B., Sette A., Luca S., Spasic M., Tortora G., Trajanoski Z., Tunici P., Vitale C., Wigginton J., Yadav M., Yu H., Maio, Michele, Lahn, Michael, Di Giacomo, Anna Maria, Covre, Alessia, Calabrò, Luana, Ibrahim, Ramy, Fox, Bernard, Siena Think Tank, Lollini, Pier-Luigi, Pulmonary Medicine, Maio, M., Lahn, M., Di Giacomo, A. M., Covre, A., Calabro, L., Ibrahim, R., Fox, B., Abrignani, S., Paola, A., Anichini, A., Ardizzoni, A., Gregorio, A., Azab, M., Ballas, M., Barberis, M., Bayless, N. L., Bell, B., Bifarini, A., Blank, C., Brodin, P., Camerini, R., Ennio, C., Ceccarelli, M., Francesca, C., Connolly, J., Sandra, C., Cornelissen, R., Eggermont, A., Eid, J., Fajgenbaum, D., Ferretti, E., Ferrone, S., Finotello, F., Flaherty, K., Ester, F., Elisabetta, F., Fridman, C. S., Fridman, W. H., Garcia, P., Gherardini, P. F., Goonewardene, A., Hacking, G., Heller, K., Hulett, T. W., Michael, I., Jacobson, D., Janek, M., Joho, S., Keer, H., Kleif, S., Kotecha, N., Kotter, M., Krogan, N., Lanzavecchia, A., Locatelli, F., Lollini, P. -L., Mantovani, A., Melacarne, A., Melillo, G., Menden, M., Minerva, D., Moretta, L., Namouni, F., Natali, P. G., Necchi, A., Nistico, P., Cosimo, P., Giuseppe, P., Pardoll, D., Paz-Ares, L., Plessala, K., Peters, S., Prins, R. M., Provendier, O., Rappuoli, R., Rescigno, M., Ruettinger, D., Seliger, B., Sette, A., Luca, S., Spasic, M., Tortora, G., Trajanoski, Z., Tunici, P., Vitale, C., Wigginton, J., Yadav, M., and Yu, H.

Subjects
0301 basic medicine, Oncology, Mesothelioma, Cancer Research, Artificial intelligence, Research areas, medicine.medical_treatment, Corona virus disease 19 (COVID-19), Glioblastoma, Immunotherapy, Melanoma, Novel treatments, PD-L1, PD1, Antibodies, Monoclonal, COVID-19, Humans, Immunity, Italy, Medical Oncology, Neoplasms, Meeting Report, 0302 clinical medicine, Monoclonal, RC254-282, Foundation (evidence), Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Immunotherapy, Novel treatments, PD1, PD-L1, Melanoma, Mesothelioma, Artificial intelligence, Glioblastoma, Corona virus disease 19 (COVID-19), 030220 oncology & carcinogenesis, Non small cell, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Antibodies, NO, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Novel treatment, Tumor microenvironment, business.industry, Cancer, medicine.disease, 030104 developmental biology, business
Abstract

Background The yearly Think Tank Meeting of the Italian Network for Tumor Biotherapy (NIBIT) Foundation, brings together in Siena, Tuscany (Italy), experts in immuno-oncology to review the learnings from current immunotherapy treatments, and to propose new pre-clinical and clinical investigations in selected research areas. Main While immunotherapies in non-small cell lung cancer and melanoma led to practice changing therapies, the same therapies had only modest benefit for patients with other malignancies, such as mesothelioma and glioblastoma. One way to improve on current immunotherapies is to alter the sequence of each combination agent. Matching the immunotherapy to the host’s immune response may thus improve the activity of the current treatments. A second approach is to combine current immunotherapies with novel agents targeting complementary mechanisms. Identifying the appropriate novel agents may require different approaches than the traditional laboratory-based discovery work. For example, artificial intelligence-based research may help focusing the search for innovative and most promising combination partners. Conclusion Novel immunotherapies are needed in cancer patients with resistance to or relapse after current immunotherapeutic drugs. Such new treatments may include targeted agents or monoclonal antibodies to overcome the immune-suppressive tumor microenvironment. The mode of combining the novel treatments, including vaccines, needs to be matched to the patient’s immune status for achieving the maximum benefit. In this scenario, specific attention should be also paid nowadays to the immune intersection between COVID-19 and cancer.

Published
2021

12. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

Author

Landi, L, D'Inca, F, Gelibter, A, Chiari, R, Grossi, F, Delmonte, A, Passaro, A, Signorelli, D, Gelsomino, F, Galetta, D, Giannarelli, D, Soto Parra, H, Minuti, G, Tiseo, M, Migliorino, M, Cognetti, F, Toschi, L, Bidoli, P, Piantedosi, F, Calabro', L, Cappuzzo, F, Landi L., D'Inca F., Gelibter A., Chiari R., Grossi F., Delmonte A., Passaro A., Signorelli D., Gelsomino F., Galetta D., Giannarelli D., Soto Parra H., Minuti G., Tiseo M., Migliorino M. R., Cognetti F., Toschi L., Bidoli P., Piantedosi F., Calabro' L., Cappuzzo F., Landi, L, D'Inca, F, Gelibter, A, Chiari, R, Grossi, F, Delmonte, A, Passaro, A, Signorelli, D, Gelsomino, F, Galetta, D, Giannarelli, D, Soto Parra, H, Minuti, G, Tiseo, M, Migliorino, M, Cognetti, F, Toschi, L, Bidoli, P, Piantedosi, F, Calabro', L, Cappuzzo, F, Landi L., D'Inca F., Gelibter A., Chiari R., Grossi F., Delmonte A., Passaro A., Signorelli D., Gelsomino F., Galetta D., Giannarelli D., Soto Parra H., Minuti G., Tiseo M., Migliorino M. R., Cognetti F., Toschi L., Bidoli P., Piantedosi F., Calabro' L., and Cappuzzo F.

Abstract

Background: Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy. Methods: Pretreated non-squamous (cohort A) and squamous (cohort B) NSCLCs included in the Italian Expanded Access Program were evaluated for nivolumab efficacy according to BoM. Results: Cohort A accounted for 1588 patients with non-squamous NSCLC, including 626 (39%) with (BoM+) and 962 (61%) without BoM (BoM-). Cohort B accounted for 371 patients with squamous histology including 120 BoM+ (32%) and 251 (68%) BoM- cases. BoM+ had lower overall response rate (ORR; Cohort A: 12% versus 23%, p < 0.0001; Cohort B: 13% versus 22%, p = 0.04), shorter progression free survival (PFS; Cohort A: 3.0 versus 4.0 months, p < 0.0001; Cohort B: 2.7 versus 5.2 months, p < 0.0001) and overall survival (OS; Cohort A: 7.4 versus 15.3 months, p < 0.0001; Cohort B: 5.0 versus 10.9 months, p < 0.0001). Moreover, BoM negatively affected outcome irrespective of performance status (PS; OS in both cohorts: p < 0.0001) and liver metastases (OS cohort A: p < 0.0001; OS Cohort B: p = 0.48). At multivariate analysis, BoM independently associated with higher risk of death (cohort A: HR 1.50; cohort B: HR 1.78). Conclusions: BoM impairs immunotherapy efficacy. Accurate bone staging should be included in clinical trials with immunotherapy.

Published
2019

14. Chemical, Textural and Thermal Analyses of Local Interactions Between Lava Flow and a Tree – Case Study From Pāhoa, Hawai’i

Author

Biren, J., Harris, A., Tuffen, H., Chevrel, Magdalena Oryaelle, Gurioli, L., Vlastelic, I., Schiavi, F., Benbakkar, M., Fonquernie, C., Calabro, L., Laboratoire Magmas et Volcans (LMV), Institut national des sciences de l'Univers (INSU - CNRS)-Université Jean Monnet - Saint-Étienne (UJM)-Institut de Recherche pour le Développement et la société-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS)-Observatoire de Physique du Globe de Clermont-Ferrand (OPGC), Institut national des sciences de l'Univers (INSU - CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Institut des Sciences de la Terre d'Orléans - UMR7327 (ISTO), Bureau de Recherches Géologiques et Minières (BRGM) (BRGM)-Observatoire des Sciences de l'Univers en région Centre (OSUC), Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS), Magma - UMR7327, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)-Bureau de Recherches Géologiques et Minières (BRGM) (BRGM)-Observatoire des Sciences de l'Univers en région Centre (OSUC), Department of Environmental Science [Lancaster], Lancaster University, ANR-10-LABX-0006,CLERVOLC,Clermont-Ferrand centre for research on volcanism(2010), ANR-16-IDEX-0001,CAP 20-25,CAP 20-25(2016), Institut national des sciences de l'Univers (INSU - CNRS)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut de Recherche pour le Développement et la société-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS)-Observatoire de Physique du Globe de Clermont-Ferrand (OPGC), and Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut national des sciences de l'Univers (INSU - CNRS)

Subjects
tree mold, Albizia tree, crystallization, basaltic pāhoehoe-lava flow, [SDU.STU.VO]Sciences of the Universe [physics]/Earth Sciences/Volcanology, basaltic pahoehoe-lava flow, cooling rate, Thermal model, combustion
Abstract

Co-auteur étranger; International audience; Because many volcanoes are densely vegetated, understanding of the interactions between active lava flows and trees is essential for robust hazard modeling. Tree molds − lava flow features generated when advancing lava engulfs and combusts trees − are widely documented but have, to date, only been described qualitatively. Detailed, quantitative studies of molds can, however, provide insights into the nature of lava-forest interactions. Here, we present a unique characterization of the chemical, textural and thermal interactions between lava and a tree (an Albizia), taking as a case type a basaltic pāhoehoe lava flow that traveled 20 km through Hawaiian rainforest on Kilauea’s East Rift Zone between June and December 2014. The dataset includes chemical analyses of lava (major, trace and volatile species) at the lava-tree contact, quantitative descriptions of lava texture (density, vesicle and crystal populations), and thermal analysis to fingerprint the devolatilization and combustion of wood as well as with cooling and crystallization of lava around the tree. We use these results to construct a three-stage thermal model to describe heat transfer between the lava and the tree, showing how the interaction facilitates combustion of wood and release of its volatile species (CO2 and H2O) into the lava, whilst triggering enhanced cooling and crystallization of lava surrounding the tree. Chemical analyses reveal that the inflating pāhoehoe at the lava-tree contact was strongly CO2-enriched (up to 1200 ppm), and textural data show that lava is denser at the contact. Moreover, lava crystallinity indicates a cooling rate of ∼70°C min–1 at the lava-tree contact, a rate well above the expected cooling rates (30°C min–1) for pāhoehoe more distant (40 m away) from the tree. We conclude that the tree had a local cooling effect on the lava that could potentially influence lava properties at larger scale if tree density, trunk diameter and moisture content are sufficiently high.

Published
2020
Full Text
View/download PDF

17. OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial

Author

Barlesi, F., primary, Vansteenkiste, J., additional, Spigel, D., additional, Ishii, H., additional, Garassino, M., additional, De Marinis, F., additional, Özgüroğlu, M., additional, Szczesna, A., additional, Polychronis, A., additional, Uslu, R., additional, Krzakowski, M., additional, Lee, J., additional, Calabro, L., additional, Frontera, O., additional, Ellers-Lenz, B., additional, Bajars, M., additional, Ruisi, M., additional, and Park, K., additional

Published
2018
Full Text
View/download PDF

20. OA 02.01 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma

Author

Kindler, H.L., primary, Novello, S., additional, Fennell, D., additional, Blumenschein, G., additional, Bearz, A., additional, Ceresoli, G., additional, Aerts, J., additional, Spicer, J., additional, Taylor, P., additional, Greystoke, A., additional, Nackaerts, K., additional, Calabro, L., additional, Burgers, S., additional, Jennens, R., additional, Sporchia, A., additional, Walter, A., additional, Siegel, J., additional, Childs, B., additional, Elbi, C., additional, and Hassan, R., additional

Published
2017
Full Text
View/download PDF

21. Use of nivolumab in elderly patients with advanced non-squamous NSCLC: Results from the Italian expanded access program (EAP)

Author

Migliorino, M.R., primary, Gelibter, A., additional, Grossi, F., additional, Fagnani, D., additional, Bordi, P., additional, Franchina, T., additional, Turci, D., additional, Di Lauro, L., additional, Cascinu, S., additional, Calabro, L., additional, Brighenti, M., additional, Tedde, N., additional, Bearz, A., additional, Giusti, S., additional, Vasile, E., additional, Surico, G., additional, Cartenì, G., additional, Marchetti, P., additional, Verderame, F., additional, and Melotti, B., additional

Published
2017
Full Text
View/download PDF

22. Riduzione dei CD34+ circolanti nella broncopneumopatia cronica ostruttiva (BPCO)

Author

HUERTAS A, TESTA U, CALABRO' L, ANTONUCCI R, PETRUCCI E, SATTA A, BONSIGNORE G, SERRA P, PALANGE P., MORICI, Giuseppe, VIGNOLA, Antonio Maurizio, BONSIGNORE, Maria Rosaria, HUERTAS A, TESTA U, CALABRO' L, ANTONUCCI R, PETRUCCI E, SATTA A, MORICI G, VIGNOLA AM, BONSIGNORE G, SERRA P, BONSIGNORE MR, and PALANGE P

Published
2004

23. Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012

Author

Maio, M., Nicolay, H. J. M., Ascierto, P. A., Belardelli, F., Camerini, R., Colombo, M. P., Queirolo, P., Ridolfi, R., Russo, V., Parisi, G., Cutaia, O., Fonsatti, E., Parmiani, G., Mennonna, D., Carluccio, S., Bellone, M., Maccalli, C., Brendolan, A., Mondino, A., Corti, A., Bondanza, A., Locatelli, F., Seliger, B., Filaci, G., Rosato, A., Pittoni, P., Tazzari, M., Rivoltini, L., Anichini, A., Vallacchi, V., Zappasodi, R., Quaglino, E., Moresco, R. M., Camisaschi, C., Calabro, L., Ferrucci, P. F., Fratta, E., Ugel, S., van Baren, N., Guidoboni, M., Covre, A., Carbone, E., Aurisicchio, L., Palmieri, G., Di Giacomo, A. M., Volonte, A., Jachetti, E., and Sangiolo, D.

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Immunology, Cancer, medicine.disease, NIBIT, Oncology, Family medicine, Immunotherapy, Networks, Cancer, Immunology, Immunotherapy, Networks, NIBIT, Immunology and Allergy, Medicine, business
Published
2013

25. Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer

Author

Di Maio, M, Leighl, Nb, Gallo, C, Feld, R, Ciardiello, F, Butts, C, Maione, P, Gebbia, V, Morgillo, F, Wierzbicki, R, Favaretto, A, Alam, Y, Cinieri, S, Siena, S, Bianco, R, Riccardi, F, Spatafora, M, Ravaioli, A, Felletti, R, Fregoni, V, Genestreti, G, Rossi, A, Mancuso, G, Fasano, M, Morabito, A, Tsao, Ms, Signoriello, S, Perrone, F, Gridelli, C, Torch, Investigators, Calabro', L, Di Maio, M., Leighl, N. B., Gallo, C., Feld, R., Ciardiello, F., Butts, C., Maione, P., Gebbia, V., Morgillo, F., Wierzbicki, R., Favaretto, A., Alam, Y., Cinieri, S., Siena, S., Bianco, Roberto, Riccardi, F., Spatafora, M., Ravaioli, A., Felletti, R., Fregoni, V., Genestreti, G., Rossi, A., Mancuso, G., Fasano, M., Morabito, A., Tsao, M. S., Signoriello, S., Perrone, F., Gridelli, C., Di Maio, M, Leighl, N, Gallo, C, Feld, R, Ciardiello, F, Butts, C, Maione, P, Gebbia, V, Morgillo, F, Wierzbicki, R, Favaretto, A, Alam, Y, Cinieri, S, Siena, S, Bianco, R, Riccardi, F, Spatafora, M, Ravaioli, A, Felletti, R, Fregoni, V, Genestreti, G, Rossi, A, Mancuso, G, Fasano, M, Morabito, A, Tsao, M, Signoriello, S, Perrone, F, Gridelli, C, and Leighl, Nb

Subjects
Oncology, Male, erlotinib, Lung Neoplasms, Health-related quality of life, NSCLC, chemotherapy, Deoxycytidine, law.invention, Randomized controlled trial, Quality of life, law, Carcinoma, Non-Small-Cell Lung, Surveys and Questionnaires, Antineoplastic Combined Chemotherapy Protocols, Surveys and Questionnaire, Quality of life analysis of TORCH, Erlotinib Hydrochloride, Prognosis, humanities, Research Design, Advanced non–small-cell lung cancer, Carcinoma, Squamous Cell, Female, Erlotinib, Randomized trial, medicine.drug, Human, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Prognosi, EGFR, First-line treatment, first-line erlotinib, second-line cisplatin/gemcitabine chemotherapy, Adenocarcinoma, NO, Follow-Up Studie, Internal medicine, advanced non-small-cell lung cancer, medicine, Humans, Lung cancer, Advanced non-small-cell lung cancer, Chemotherapy, Quality of life analysis of TORCH , first-line erlotinib , second-line cisplatin/gemcitabine chemotherapy, advanced non-small-cell lung cancer, Aged, Neoplasm Staging, Salvage Therapy, Antineoplastic Combined Chemotherapy Protocol, business.industry, Questionnaire, Cancer, Quinazoline, medicine.disease, Interim analysis, Gemcitabine, Surgery, Lung Neoplasm, quality of life, Quinazolines, Carcinoma, Large Cell, Cisplatin, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

INTRODUCTION:: The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced non-small-cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. standard inverse sequence. The trial, designed to test noninferiority in overall survival, was stopped at interim analysis because of inferior survival in the experimental arm. Quality of life (QoL), a secondary outcome, is reported here. METHODS:: QoL was assessed at baseline and every 3 weeks during first-line, using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 and QLQ-lung cancer specific module (LC13). Mean changes from baseline within arms were reported. QoL response and time-to-deterioration of QoL using a competing-risk approach were compared between treatment arms. RESULTS:: Six hundred and thirty patients (83%) completed baseline questionnaires. Compliance was affected by differential treatment efficacy, but was similar between arms for patients without progression or death. Significant differences in QoL responses were observed favoring chemotherapy for pain, sleeping, dyspnea, diarrhea, and favoring erlotinib for vomiting, constipation, sore mouth, and alopecia. In the small subset of patients with EGFR-mutated tumors, all selected items (global QoL, physical functioning, cough, dyspnea and pain) improved, whereas worsening or no change was observed in wild-type patients. Improvement was particularly evident in the first-line erlotinib arm as for global QoL and physical functioning. CONCLUSIONS:: QoL was impacted by differential toxicity and efficacy between arms. Functional domains and global QoL did not differ, although some symptoms were better controlled with chemotherapy in unselected non-small-cell lung cancer patients. © 2012 by the International Association for the Study of Lung Cancer.

Published
2012

27. Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009

Author

Maio, M. (Michele), Nicolay, H.J.M. (Hugues J.M.), Ascierto, P.A. (Paolo Antonio), Belardelli, F. (Filipppo), Camerini, R. (Roberto), Colombo, M.P. (Mario P.), Queirolo, P. (Paola), Ridolfi, R. (Ruggero), Russo, V. (Vicenzo), Fonsati, E. (Ester), Parmiani, G. (Giorgio), Allavena, P. (P), Anichini, A. (A), Bellone, M. (M), Bronstein, J. (Judith), Calabro, L. (L), Camisaschi, C. (C), Castelli, C. (Chiara), Danova, M. (M), Di-Giacomo, A.M. (A.M.), Di-Nicola, M. (Massimo), Ferlazzo, G. (G.), Giovannoni, L. (L.), Hwu, P. (Patrick), Lehmann, F. (F.), Maccalli, C. (Cristina), Melero, I. (Ignacio), Monsurro, V. (V), Montagna, D. (D.), Moschella, F. (F.), Ponzoni, M. (M), Protti, M.P. (M.P.), Puccetti, P. (P), Sangiolo, D. (D.), and Shuler, G. (G)

Subjects
Neoplasms/therapy
Published
2010

28. Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT)

Author

Maio, M, Nicolay, Hj, Ascierto, Pa, Belardelli, F, Camerini, R, Colombo, Mp, Queirolo, P, Ridolfi, R, Russo, V, Fonsatti, E, Parmiani, G, Calabro', L, and Nibit, Collaborators

Subjects
Angiogenesis Inhibitors, Cancer Vaccines, Dendritic Cells, Humans, Immune Tolerance, Immunotherapy, Adoptive, Neoplasms, Tumor Escape, Vaccination, Adoptive, Immunotherapy, NO
Published
2010

31. Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial

Author

Gebbia, V, Gridelli, C, Verusio, C, Frontini, L, Aitini, E, Daniele, B, Gamucci, T, Mancuso, G, Di Maio, M, Gallo, C, Perrone, F, Morabito, A, Calabro', L, and And, Coauthors

Subjects
Adult, Male, Lung Neoplasms, Socio-culturale, Docetaxel, Middle Aged, Medication Adherence, Survival Rate, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Humans, Female, Taxoids, Aged
Abstract

Doublet chemotherapy is more effective than single-agent as first line treatment of advanced non-small-cell lung cancer (NSCLC). No reliable information instead is available on the effect of doublets in second line treatment. The aim of DISTAL-2 study was to compare two doublets containing docetaxel with single agent docetaxel as second line treatment of patients with NSCLC (ClinicalTrials.gov id.:.NCT00345059).NSCLC patients, aged75, PS 0-2, who had failed platinum-based chemotherapy, were randomly assigned with a 3:1:1 ratio to: arm A, weekly docetaxel (33.3mg/m(2) on days 1, 8, 15 q 4 weeks); arm B, weekly docetaxel (30 mg/m(2) on days 1, 8, 15) plus gemcitabine (800 mg/m(2) on days 1, 8 q 4 weeks) or plus vinorelbine (20mg/m(2) on days 1, 8 q 4 weeks) depending on which of the two had been used in first line; arm C, weekly docetaxel (as in arm B) plus capecitabine (625 mg/m(2) twice daily on days 5-18 q 4 weeks). Primary end-point was overall survival (OS). Two comparisons were planned: arm B vs. A and arm C vs. A. Overall, 375 patients had to be randomized. Response was assessed by RECIST, quality of life (QoL) by EORTC questionnaires.84 patients were randomized from May 2005 to December 2006, when the trial was prematurely stopped due to the slow accrual. After 62 deaths, median OS was 40.0 weeks in arm A, 32.6 weeks in arm B (p=0.18 vs. A) and 39.7 weeks in arm C (p=0.90 vs. A). Response rate was 6.4, 16.7 and 5.3%, and median progression-free survival was 12.4, 13.1 and 11.9 weeks, for arms A, B and C, respectively. Patients in arm B had significantly more grade 3-4 haematological and non-haematological toxicity compared to arm A, and patients in arm C had significantly more grade 3-4 non-haematological toxicity compared to arm A. No relevant differences were found in QoL analysis, with the exception of significant worsening in appetite, vomiting and hemoptysis for patients in arm B.Due to early termination, the trial does not have the planned statistical power. However, available data do not support the role of docetaxel-based combination chemotherapy as second line in advanced NSCLC.

Published
2009

33. Valsartan for prevention of recurrent atrial

Author

Disertori, M, Latini, R, Maggioni, Ap, Barlera, S, Di Pasquale, G, Franzosi, Mg, Lucci, D, Staszewsky, L, Tognoni, G, Delise, P, Bertocchi, F, Maiocchi, G, Geraci, E, Correale, E, Lombardi, F, Mugelli, A, Urso, R, Scardi, S, Fabbri, G, Bartolomei, B, Barbato, G, Carbonieri, E, Ciricugno, S, Cosmi, F, Pratola, C, Rossi, Mg, Sciarra, L, Zeni, P, Ceseri, M, Atzori, A, Bambi, F, Baviera, M, Bianchini, F, Cfenicia, E, Gianfriddo, M, Lonardo, G, Luise, A, Nota, R, Orlando, Me, Petrolo, R, Pierattini, C, Pierota, V, Ragno, A, Serio, C, Tafi, A, Tellaroli, E, Masson, S, Vago, T, Gramenzi, S, Orso, F, Suliman, I, Nicolis, E, Casola, C, Dall'Osso, D, Gorini, M, Bianchini, E, Cabiddu, S, Cangioli, I, Carnaghi, A, Cipressa, Ml, Cipressa, L, Galbiati, L, Lorimer, A, Priami, P, Moccetti, T, Vaghi, F, Capello, Af, Rossetti, G, Viada, E, Morena, L, Delucchi, M, Reynaud SG, Allemano, P, Massobrio, N, Gavazzi, A, Taddei, F, Mor, Da, Bortolini, F, Lorini, M, Inama, G, Durin, O, Pirelli, S, Spotti, A, Procopio, R, Cuzzucrea, D, Gentile, G, Margonato, A, Bassanelli, G, Tavazzi, L, Buzzi, Mp, Rordorf, R, Gualco, A, Opasich, C, Gronda, E, Genovese, L, Mattioli, R, Donatelli, F, Uriarte, Ja, Rauhe, W, Bertagnolli, C, Canestrini, S, Stefenelli, C, Cioffi, G, Giovanelli, C, Rigatelli, G, Boni, S, Pasini, A, Sitta, N, Sacchetta, A, Borgese, L, Sciascia, R, Targa L, Raviele, A, Madalosso, M, Bertaglia, E, Zoppo, Fc, Capanna, M, Fiorencis, R, Baracca, E, Rossi, R, Rossi, I, Trappolin, R, Morgera, T, Barducci, E, Baldin, Mg, Gobbo, G, Zardo, F, Hrovatin, E, Mos, L, Vriz, O, Sinagra, G, Aleksova, A, Mazzone, C, Fresco, C, Rubartelli, P, Moroni, La, Camerieri, A, Piana, M, Mureddu, R, Bertoli, D, Petacchi, R, Pancaldi, Lg, Gabrieli, L, Urbinati, S, Pedone, C, Di Niro, M, Brunelli, A, Bosi, S, Censi, S, Moruzzi, P, Pastori, P, Modena, Mg, Malavasi, V, Mezzetti, M, Melandri, F, Zuppiroli, A, Fazi, A, Testa, R, Venturini, E, Mazzinghi, F, Cosmi, D, Santoro, Gm, Minneci, C, Galli, M, Paperini, L, Bovenzi, Fm, Cortigiani, L, Cocchieri, M, Severini, D, Arcuri, Gm, Bagliani, G, Bernardinangeli, M, Proietti, G, Bocconcelli, P, Pierantozzi, A, Monti, F, Giamundo, L, Tancredi, P, Rossini, E, Bianchi, C, Bettiol, F, Giovannini, E, Fera, Ms, Santini, M, Bianconi, L, Boccanelli, A, Morosetti, P, Volpe, M, Facciolo, C, Vacri, A, Romanazzi, F, Napoletano, C, Piccioni, Ll, Candelmo, F, De Marco, G, Arnese, Mr, Vetrano, A, Prinzi, D, De Rosa, P, Capuano, V, Torre, S, D'Onofrio, A, Ammendola, E, Chiariello, M, Filardi, Pp, Battista, R, De Fusco, A, Molero, U, Iervoglini, A, Stefanelli, S, Fattore, L, Bosco, B, Liguori, A, Padula, G, De Luca, I, Sorino, M, Colonna, P, D'Agostino, C, Pierfelice, O, Pettinati, G, Muscella, A, De Lorenzi, E, Falco, M, Giannattasio, C, Baldi, N, Clemente, Ma, D'Alessandro, B, Truncellito, L, Arabia, F, Ciconte, Va, Perticone, F, Ruberto, C, Buffon, A, Tomaselli, C, De Rosa, F, Mazza, S, Zampaglione, G, Pirozzi, Am, Butera, A, Levato, M, Musacchio, D, Polimeni, Rm, Lacquaniti, V, Pulitanò, G, Ruggeri, A, Provenzano, A, Cuccurullo, O, Musolino, M, Marrari, A, Anastasio, L, Schiavello, M, Comito, Mg, Gulizia, Mm, Francese GM, Vasquez, L, Coppolino, C, Casale, A, D'Urso, G, Oliva, G, Giordano, U, Andolina, S, Sanfilippo, N, Ingrillì, F, Accardo, S, Grasso, S, Buffa, L, Bambi, Serra E., Baviera, M., Bianchini, F., Fenicia, E., Gianfriddo, M., Lonardo, G., Luise, A., Nota, R., Orlando, M. E., Petrolo, R., Pierattini, C., Pierota, V., Ragno, A., Serio, C., Tafi, A., Tellaroli, E., Masson, Core Laboratories — S., Latini, R., Vago (Biomarkers), T., Staszewsky, L., Gramenzi (Echocardiography), S., Orso, F., Suliman (Electrocardiography), I., Nicolis, Database Management and Statistics — E., Casola, C., Barlera, S., Dall'Osso, D., Gorini, M., Lucci, D., Regulatory, Administrative, Bianchini, and Secretariat — E., Cabiddu, S., Cangioli, I., Carnaghi, A., Cipressa, M. L., Cipressa, L., Galbiati, L., Lorimer, A., Priami, P., Moccetti, Participating Centers and Investigators — Switzerland: Lugano (T., Rossi, M. G., Vaghi), F., Capello), Italy: Piemonte: Asti (A. F. L., Rossetti, Cuneo (G., Viada, E., Morena), L., Delucchi, Saluzzo (M., Reynaud, S. G., Allemano), P., Massobrio), Torino Valdese (N., Gavazzi, Lombardia: Bergamo (A., Taddei), F., Mor), Brescia (D. A., Bortolini, Chiari (F., Lorini), M., Inama, Crema (G., Durin), O., Pirelli, Cremona (S., Spotti, A., Procopio), R., Cuzzucrea, Giussano (D., Gentile), G., Margonato, Milano San Raffaele (A., Bassanelli), G., Tavazzi, Pavia San Matteo (L., Buzzi, M. P., Rordorf), R., Gualco, Pavia Fondazione Salvatore Maugeri (A., Opasich), C., Gronda, Rozzano (E., Genovese), L., Mattioli, Sesto San Giovanni (R., Donatelli), F., Salerno Uriarte), Varese (J. A., Rauhe), P. A. Bolzano: Bolzano (W., Bertagnolli, P. A. Trento: Cles (C., Canestrini), S., Stefenelli, Trento Villa Bianca (C., Cioffi), G., Disertori, Trento Santa Chiara (M., Zeni, P., Giovanelli), C., Rigatelli, Veneto: Bovolone (G., Boni, S., Pasini), A., Sitta), Conegliano Santa Maria dei Battuti (N., Sacchetta, Conegliano Veneto De Gironcoli (A., Borgese, L., Sciascia), R., Targa), Este (L., Raviele, Mestre (A., Madalosso), M., Bertaglia, Mirano (E., Zoppo), F. C., Capanna, Porto Viro (M., Fiorencis), R., Baracca), Rovigo (E., Rossi, San Bonifacio (R., Carbonieri, E., Rossi), I., Trappolin), Villafranca di Verona (R., Morgera, Friuli Venezia Giulia: Monfalcone (T., Barducci), E., Baldin, Palmanova (M. G., Gobbo), G., Zardo, Pordenone (F., Hrovatin), E., Mos, San Daniele del Friuli (L., Vriz), O., Sinagra, Trieste Az. Ospedaliera-Universitaria Ospedali Riuniti (G., Aleksova), A., Scardi, Trieste Az. Servizi Sanitari n. 1 Triestina (S., Mazzone), C., Fresco), Udine (C., Rubartelli, Liguria: Genova-Sampierdarena (P., Moroni), L. A., Camerieri), Genova-Voltri (A., Piana), Imperia (M., Mureddu), Pietra Ligure (R., Bertoli, Sarzana-Loc. S. Caterina (D., Petacchi), R., Pancaldi, Emilia Romagna: Bentivoglio (L. G., Gabrieli), L., Urbinati, Bologna Bellaria (S., Pedone), C., Di Pasquale, Bologna Maggiore (G., Di Niro, M., Brunelli), A., Bosi, Cotignola (S., Censi), S., Pratola), Ferrara (C., Moruzzi, Fidenza (P., Pastori), P., Modena, Modena (M. G., Malavasi), V., Mezzetti), Rimini (M., Melandri), Sassuolo (F., Zuppiroli, Toscana: Bagno a Ripoli (A., Fazi), A., Testa, Cecina (R., Venturini, E., Mazzinghi), F., Cosmi, Cortona (F., Cosmi), D., Santoro, Firenze Nuovo Osp. S Giovanni di Dio (G. M., Minneci), C., Galli, Livorno (M., Paperini), L., Bovenzi, Lucca (F. M., Cortigiani), L., Cocchieri, Umbria: Città di Castello (M., Severini, D., Arcuri), G. M., Bagliani), Foligno (G., Bernardinangeli, Terni (M., Proietti, G., Proietti), G., Bocconcelli, Marche: Pesaro (P., Pierantozzi), A., Monti, Lazio: Albano Laziale (F., Giamundo), L., Tancredi, Formia (P., Rossini), E., Bianchi), Roma Centro Traumatologico Ortopedico (C., Roma San Camillo, Bettiol), Cardiologia Riabilitativa e Preventiva (F., Giovannini, Cardiologia I (E., Fera), M. S., Santini, Roma San Filippo Neri (M., Bianconi), L., Boccanelli, Roma San Giovanni (A., Morosetti), P., Volpe, Roma Sant'Andrea (M., Facciolo), C., Vacri, Abruzzo: Penne (A., Romanazzi), F., Napoletano, Teramo (C., Piccioni), L. L., Candelmo), Campania: Avellino (F., De Marco, Aversa (G., Arnese), M. R., Vetrano), Caserta (A., Prinzi, Giugliano in Campania (D., De Rosa), P., Capuano, Mercato San Severino (V., Torre), S., D'Onofrio, Napoli Azienda Ospedaliera Monaldi (A., Ammendola), E., Chiariello, Napoli Policlinico Universitario Federico II (M., Perrone Filardi), P., Battista, Piedimonte Matese (R., De Fusco), A., Molero), Pozzuoli (U., Iervoglini, San Felice a Cancello (A., Stefanelli), S., Fattore, Santa Maria Capua Vetere (L., Bosco), B., Liguori, Vallo della Lucania (A., Padula), G., De Luca, Puglia: Bari Ospedale Consorziale Policlinico (I., Sorino, M., Colonna), P., D'Agostino, Bari-Carbonara (C., Pierfelice), O., Pettinati, Casarano (G., Muscella), A., De Lorenzi, Scorrano (E., Falco), M., Giannattasio), Taranto Villa Verde (C., Baldi), Taranto Santissima Annunziata (N., Clemente), Basilicata: Matera (M. A., D'Alessandro, Policoro (B., Truncellito), L., Arabia, Calabria: Catanzaro Pugliese (F., Ciconte), V. A., Perticone, Catanzaro Germaneto (F., Ruberto), C., Buffon, Cosenza Santissima Annunziata (A., Tomaselli), C., De Rosa, Cosenza Mariano Santo (F., Mazza), S., Zampaglione, Crotone (G., Pirozzi), A. M., Butera, Lamezia Terme (A., Levato), M., Musacchio), Paola (D., Polimeni, Polistena (R. M., Lacquaniti), V., Pulitanò, Reggio Calabria (G., Ruggeri), A., Provenzano), Rogliano (A., Cuccurullo), San Marco Argentano (O., Musolino, Scilla (M., Marrari), A., Anastasio, Soriano Calabro (L., Schiavello), M., Comito), Vibo Valentia (M. G. A., Gulizia, Sicilia: Catania (M. M., Francese), G. M., Vasquez, Milazzo (L., Coppolino), C., Casale, Nicosia (A., D'Urso), G., Oliva, Palermo Civico e Benfratelli (G., Giordano, U., Andolina), S., Sanfilippo, Palermo Villa Sofia (N., Ingrillì), F., Accardo), Palermo Buccheri La Ferla (S., Grasso, Palermo Cervello (S., Buffa), L., and Sardegna: Cagliari Brotzu, (E. Serra).

Published
2009

36. Circulating haemopoietic and endothelial cells are decreased in COPD

Author

Palange, P, Testa, U, Huertas, A, Calabro', L, Antonucci, R, Pelosi, E, Pasquini, L, Satta, A, Monici, G, Vignola, Ma, and Monsignore, Mr

Subjects
exercise, hypoxia, growth factors, CD34+ cells, chronic obstructive pulmonary disease, exercise, growth factors, hypoxia, CD34+ cells, NO, chronic obstructive pulmonary disease
Published
2006

38. Future perspectives in melanoma research. Meeting report from the 'Melanoma Bridge. Napoli, December 2nd-4th 2012'

Author

Ascierto, PA, Grimaldi, AM, Acquavella, N, Borgognoni, L, Calabro, L, Cascinelli, N, Cesano, A, Del Vecchio, M, Eggermont, AM, Faries, M, Ferrone, S, Fox, BA, Gajewski, TF, Galon, J, Gnjatic, S, Gogas, H, Kashani-Sabet, M, Kaufman, HL, Larkin, J, Lo, RS, Mantovani, A, Margolin, K, Melief, C, McArthur, G, Palmieri, G, Puzanov, I, Ribas, A, Seliger, B, Sosman, J, Suenaert, P, Tarhini, AA, Trinchieri, G, Vidal-Vanaclocha, F, Wang, E, Ciliberto, G, Mozzillo, N, Marincola, FM, Thurin, M, Ascierto, PA, Grimaldi, AM, Acquavella, N, Borgognoni, L, Calabro, L, Cascinelli, N, Cesano, A, Del Vecchio, M, Eggermont, AM, Faries, M, Ferrone, S, Fox, BA, Gajewski, TF, Galon, J, Gnjatic, S, Gogas, H, Kashani-Sabet, M, Kaufman, HL, Larkin, J, Lo, RS, Mantovani, A, Margolin, K, Melief, C, McArthur, G, Palmieri, G, Puzanov, I, Ribas, A, Seliger, B, Sosman, J, Suenaert, P, Tarhini, AA, Trinchieri, G, Vidal-Vanaclocha, F, Wang, E, Ciliberto, G, Mozzillo, N, Marincola, FM, and Thurin, M

Abstract

Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving targeted and immune-based treatments for melanoma. After decades of unsuccessful attempts to finding a more effective cure in the treatment of melanoma now we have several drugs active in melanoma. The possibility to use these drugs in combination to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy represent new concepts and approaches in the clinical management of melanoma. The third "Melanoma Research: "A bridge from Naples to the World" meeting, shortened as "Bridge Melanoma Meeting" took place in Naples, December 2 to 4th, 2012. The four topics of discussion at this meeting were: advances in molecular profiling and novel biomarkers, combination therapies, novel concepts toward integrating biomarkers and therapies into contemporary clinical management of patients with melanoma across the entire spectrum of disease stage, and the knowledge gained from the biology of tumor microenvironment across different tumors as a bridge to impact on prognosis and response to therapy in melanoma. This international congress gathered more than 30 international faculty members who in an interactive atmosphere which stimulated discussion and exchange of their experience regarding the most recent advances in research and clinical management of melanoma patients.

Published
2013

39. Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells

Author

De Nardo, C, Fonsatti, E, Sigalotti, L, Calabro', L, Colizzi, F, Cortini, E, Coral, S, Altomonte, M, and Maio, M

Subjects
Glycosylphosphatidylinositols, Drug Resistance, Tumor Cells, Cultured, Socio-culturale, Gene Expression, Humans, Protein Isoforms, CD59 Antigens, Complement System Proteins, Melanoma, Recombinant Proteins
Abstract

Protectin (CD59) is a glycosylphosphatidylinositol (GPI)-anchored cell membrane glycoprotein, broadly expressed on melanocytic cells, that represents the main restriction factor of complement (C)-mediated lysis of human melanoma cells. Levels of CD59 expression may impair the clinical efficacy of C-activating monoclonal antibodies (mAb); thus, we investigated the molecular mechanisms underlying the lack of CD59 expression in selected melanoma cells. Serological and biochemical analyses showed that MeWo melanoma cells expressed CD59 neither at cell surface nor at cytoplasmic levels; however, no critical mutations were identified in their CD59 mRNA. Consistently, MeWo CD59 cDNA (MeWo-CD59) was appropriately translated when transfected into the CD59-positive Mel 100 melanoma cells, and into the CD59-negative Nalm-6 pre-B leukemia cells that acquired resistance to C. In contrast, transfection of MeWo cells with CD59 cDNA from Mel 275 melanoma cells did not induce CD59 expression; however, their transfection with the CD59-TM chimeric construct, obtained by replacing the GPI-anchoring signal of MeWo-CD59 with the transmembrane tail of the human low-density lipoprotein receptor, induced the expression of a C-protective transmembrane form of CD59. These data, together with the absent expression of additional GPI-anchored proteins (i.e., CD55), suggest that defects in the biosynthesis and/or processing of GPI-anchored proteins underlie the lack of CD59 expression in MeWo cells. Further unveiling of the molecular mechanism that turns off CD59 expression in human melanoma cells will help to set-up more effective therapeutic strategies utilizing C-activating mAb in melanoma patients.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results